Imperative Care Obtains Colombia Approval for its ADVANCE First-In-Human study

Bogota, Colombia. On September 28, 2023, INVIMA, the regulatory agency of Colombia, approved Imperative Care, Inc.'s ADVANCE first-in-human study, which will be conducted at one research center in Barranquilla. The ADVANCE study aims to recruit up to 15 subjects from Colombia and will last for approximately five years. Imperative Care, Inc. is a medical technology company based in Campbell, California, that specializes in developing treatments for stroke and other ischemic diseases. Founded in 2016 by neurointerventionist L. Nelson “Nick” Hopkins, MD, and entrepreneur Fred Khosravi, Imperative Care has expanded its focus from stroke care to include treatments for other ischemic conditions such as pulmonary embolism and peripheral vascular disease. Imperative Care is committed to elevating patient care across the entire journey, from detection through recovery, by addressing gaps in treatment and care. The company emphasizes a physician-driven approach to innovation, ensuring that front-line doctors' needs, perspectives, and ideas are at the center of its research and development process. This approach is supported by robust clinical data from large, prospective, multicenter trials and smaller, single-center studies.

The company has achieved several milestones, including FDA clearances for its innovative stroke and vascular products, and has treated thousands of patients with its technologies. Imperative Care's strategic agility, focus on clinical insights, and collaboration with clinicians have been crucial to its success in bringing more care to patients suffering from stroke and other vascular diseases.

Source: INVIMA's Medical Device Committee, September 28, 2023 meeting minutes.